N/A
N=14
Effect of Ondansetron for Withdrawal Symptoms
Substance Withdrawal Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT00695864 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Change in Withdrawal Symptoms With Placebo and With Ondansetron — -22.08; -42.71 Percent change
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ondansetron and Placebo crossover (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Jul 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Withdrawal Symptoms With Placebo and With Ondansetron |
-22.08; -42.71 | — |
Summary
We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications. This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to determine whether this is affective.
Eligibility Criteria
Inclusion Criteria:-Over 18 years of age
- No medical contraindications to medication
- Able to fulfill research procedures Exclusion Criteria:-Subjects who are unable to respond to our questionnaires or to stimuli as required by the experimental protocol will be excluded.
- Subjects will be excluded if they have a history of significant psychiatric disorders that would prevent them from engaging in a treatment program.
- Participating in other studies that would interfere with the procedures in this study
- Known or apparent pregnancy
Data sourced from ClinicalTrials.gov (NCT00695864). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.